Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm Announces First Patient Treated in St Vincent's Hospital, Sydney Radiotherapy Study

- Combination of NOX66 + internal radiotherapy

- Late-stage prostate cancer patients

- Safety and efficacy study

16 November 2017, Sydney: Noxopharm (ASX:NOX) today announces the treatment of the first patient in the LUPIN study.

The LUPIN Study is an Investigator-Initiated clinical trial being run at St Vincent’s Hospital, Sydney, with Dr Louise Emmett as the Principal Investigator.


For further information please download PDF attached:
Download this document